Do analysts rate MDRX or SDGR?

Schrodinger has a consensus price target of $20.80, indicating a potential downside of 31.71%. Given Schrodinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrodinger is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Schrodinger 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings & valuation, MDRX or SDGR?

Veradigm has higher revenue and earnings than Schrodinger. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.40 N/A N/A N/A Schrodinger $255.87M 8.79 -$103.26M -$0.74 N/A

Do analysts rate CERT or MDRX?

Certara presently has a consensus target price of $8.45, indicating a potential downside of 9.53%. Given Certara's stronger consensus rating and higher possible upside, equities analysts clearly believe Certara is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Certara 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.42 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, CERT or MDRX?

Veradigm has higher revenue and earnings than Certara. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Certara $418.84M 3.40 -$1.60M -$0.45 N/A Veradigm $1.53B 0.40 N/A N/A N/A

Do analysts rate MDRX or GDRX?

GoodRx has a consensus target price of $4.23, indicating a potential upside of 29.27%. Given GoodRx's stronger consensus rating and higher probable upside, analysts clearly believe GoodRx is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GoodRx 3 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.08

Which has better valuation and earnings, MDRX or GDRX?

GoodRx has lower revenue, but higher earnings than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.40 N/A N/A N/A GoodRx $796.85M 1.41 $30.44M $0.04 81.75

Is MDRX or GDRX more profitable?

GoodRx has a net margin of 2.07% compared to Veradigm's net margin of 0.00%. GoodRx's return on equity of 7.22% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A GoodRx 2.07% 7.22% 2.53%

Do analysts recommend TDOC or MDRX?

Teladoc Health currently has a consensus price target of $7.54, indicating a potential upside of 32.79%. Given Teladoc Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Teladoc Health is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teladoc Health 1 Sell rating(s) 10 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.25 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, TDOC or MDRX?

Veradigm has lower revenue, but higher earnings than Teladoc Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teladoc Health $2.53B 0.41 -$200.32M -$0.99 N/A Veradigm $1.53B 0.40 N/A N/A N/A

Do analysts recommend MDRX or HSTM?

HealthStream has a consensus target price of $27.00, suggesting a potential downside of 11.07%. Given HealthStream's stronger consensus rating and higher probable upside, analysts plainly believe HealthStream is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 HealthStream 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, MDRX or HSTM?

HealthStream has lower revenue, but higher earnings than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.40 N/A N/A N/A HealthStream $304.06M 2.92 $18.34M $0.72 42.17

Veradigm (MDRX) Competitors

$5.00 -0.14 (-2.72%)

As of 10/1/2026 12:55 PM Eastern

Compare

MDRX vs. SDGR, CERT, GDRX, TDOC, and HSTM

Should you buy Veradigm stock or one of its competitors? Veradigm's main competitors and comparable companies include Schrodinger (SDGR), Certara (CERT), GoodRx (GDRX), Teladoc Health (TDOC), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Veradigm compare to Schrodinger?

Veradigm (NASDAQ:MDRX) and Schrodinger (NASDAQ:SDGR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Veradigm has a net margin of 0.00% compared to Schrodinger's net margin of -20.98%. Veradigm's return on equity of 0.00% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Schrodinger	-20.98%	-16.37%	-8.19%

In the previous week, Schrodinger had 3 more articles in the media than Veradigm. MarketBeat recorded 3 mentions for Schrodinger and 0 mentions for Veradigm. Schrodinger's average media sentiment score of 1.24 beat Veradigm's score of 0.68 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Positive
Schrodinger	Positive

Veradigm has higher revenue and earnings than Schrodinger.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.40	N/A	N/A	N/A
Schrodinger	$255.87M	8.79	-$103.26M	-$0.74	N/A

Schrodinger has a consensus price target of $20.80, indicating a potential downside of 31.71%. Given Schrodinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrodinger is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Schrodinger	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Veradigm has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

79.1% of Schrodinger shares are held by institutional investors. 2.3% of Veradigm shares are held by insiders. Comparatively, 10.1% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Schrodinger beats Veradigm on 9 of the 14 factors compared between the two stocks.

How does Veradigm compare to Certara?

Certara (NASDAQ:CERT) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Certara has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

74.0% of Certara shares are owned by institutional investors. 1.1% of Certara shares are owned by company insiders. Comparatively, 2.3% of Veradigm shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Veradigm has a net margin of 0.00% compared to Certara's net margin of -16.75%. Certara's return on equity of 3.86% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Certara	-16.75%	3.86%	2.65%
Veradigm	N/A	N/A	N/A

Certara presently has a consensus target price of $8.45, indicating a potential downside of 9.53%. Given Certara's stronger consensus rating and higher possible upside, equities analysts clearly believe Certara is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Certara had 7 more articles in the media than Veradigm. MarketBeat recorded 7 mentions for Certara and 0 mentions for Veradigm. Certara's average media sentiment score of 0.77 beat Veradigm's score of 0.68 indicating that Certara is being referred to more favorably in the media.

Company	Overall Sentiment
Certara	Positive
Veradigm	Positive

Veradigm has higher revenue and earnings than Certara.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$418.84M	3.40	-$1.60M	-$0.45	N/A
Veradigm	$1.53B	0.40	N/A	N/A	N/A

Summary

Certara beats Veradigm on 11 of the 15 factors compared between the two stocks.

How does Veradigm compare to GoodRx?

Veradigm (NASDAQ:MDRX) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, GoodRx had 1 more articles in the media than Veradigm. MarketBeat recorded 1 mentions for GoodRx and 0 mentions for Veradigm. GoodRx's average media sentiment score of 0.93 beat Veradigm's score of 0.68 indicating that GoodRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Positive
GoodRx	Positive

63.8% of GoodRx shares are held by institutional investors. 2.3% of Veradigm shares are held by insiders. Comparatively, 5.9% of GoodRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GoodRx has lower revenue, but higher earnings than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.40	N/A	N/A	N/A
GoodRx	$796.85M	1.41	$30.44M	$0.04	81.75

Veradigm has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

GoodRx has a net margin of 2.07% compared to Veradigm's net margin of 0.00%. GoodRx's return on equity of 7.22% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
GoodRx	2.07%	7.22%	2.53%

GoodRx has a consensus target price of $4.23, indicating a potential upside of 29.27%. Given GoodRx's stronger consensus rating and higher probable upside, analysts clearly believe GoodRx is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

GoodRx beats Veradigm on 13 of the 14 factors compared between the two stocks.

How does Veradigm compare to Teladoc Health?

Teladoc Health (NYSE:TDOC) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Teladoc Health currently has a consensus price target of $7.54, indicating a potential upside of 32.79%. Given Teladoc Health's stronger consensus rating and higher possible upside, equities analysts plainly believe Teladoc Health is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Veradigm has lower revenue, but higher earnings than Teladoc Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$2.53B	0.41	-$200.32M	-$0.99	N/A
Veradigm	$1.53B	0.40	N/A	N/A	N/A

76.8% of Teladoc Health shares are held by institutional investors. 0.7% of Teladoc Health shares are held by company insiders. Comparatively, 2.3% of Veradigm shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Veradigm has a net margin of 0.00% compared to Teladoc Health's net margin of -7.13%. Veradigm's return on equity of 0.00% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-7.13%	-12.15%	-5.83%
Veradigm	N/A	N/A	N/A

In the previous week, Teladoc Health had 10 more articles in the media than Veradigm. MarketBeat recorded 10 mentions for Teladoc Health and 0 mentions for Veradigm. Veradigm's average media sentiment score of 0.68 beat Teladoc Health's score of 0.62 indicating that Veradigm is being referred to more favorably in the news media.

Company	Overall Sentiment
Teladoc Health	Positive
Veradigm	Positive

Teladoc Health has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Summary

Teladoc Health beats Veradigm on 8 of the 14 factors compared between the two stocks.

How does Veradigm compare to HealthStream?

Veradigm (NASDAQ:MDRX) and HealthStream (NASDAQ:HSTM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

HealthStream has a consensus target price of $27.00, suggesting a potential downside of 11.07%. Given HealthStream's stronger consensus rating and higher probable upside, analysts plainly believe HealthStream is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

HealthStream has a net margin of 6.60% compared to Veradigm's net margin of 0.00%. HealthStream's return on equity of 6.81% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
HealthStream	6.60%	6.81%	4.64%

In the previous week, HealthStream had 2 more articles in the media than Veradigm. MarketBeat recorded 2 mentions for HealthStream and 0 mentions for Veradigm. HealthStream's average media sentiment score of 1.44 beat Veradigm's score of 0.68 indicating that HealthStream is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Positive
HealthStream	Positive

HealthStream has lower revenue, but higher earnings than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.40	N/A	N/A	N/A
HealthStream	$304.06M	2.92	$18.34M	$0.72	42.17

69.6% of HealthStream shares are held by institutional investors. 2.3% of Veradigm shares are held by company insiders. Comparatively, 20.4% of HealthStream shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Veradigm has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Summary

HealthStream beats Veradigm on 11 of the 13 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDRX vs. The Competition

Export

Metric	Veradigm	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$611.50M	$1.76B	$7.23B	$13.08B
Dividend Yield	N/A	3.95%	2.53%	15.88%
P/E Ratio	23.25	21.24	272.65	25.80
Price / Sales	0.40	86.21	607.73	90.99
Price / Cash	N/A	31.91	77.38	51.29
Price / Book	N/A	6.19	10.51	6.26
Net Income	N/A	-$26.60M	$3.50B	$360.95M
7 Day Performance	N/A	-1.11%	-2.01%	-1.80%
1 Month Performance	6.38%	-0.39%	-6.41%	-4.02%
1 Year Performance	6.38%	-20.57%	8.96%	2.18%

Veradigm Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDRX Veradigm	N/A	$5.00 -2.7%	N/A	+6.4%	$611.50M	$1.53B	23.25	8,000	Gap Down
SDGR Schrodinger	1.2872 of 5 stars	$28.85 -2.0%	$20.50 -28.9%	+43.6%	$2.13B	$255.87M	N/A	850	Positive News
CERT Certara	1.65 of 5 stars	$9.03 +1.6%	$8.28 -8.4%	-30.1%	$1.38B	$418.84M	N/A	1,576	News Coverage Analyst Upgrade
GDRX GoodRx	4.0301 of 5 stars	$3.37 +0.1%	$4.23 +25.6%	-35.0%	$1.15B	$796.85M	84.15	697
TDOC Teladoc Health	3.2417 of 5 stars	$6.12 -0.4%	$7.54 +23.2%	-27.1%	$1.11B	$2.53B	N/A	5,600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDRX) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradigm (MDRX) Competitors

MDRX vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does Veradigm compare to Schrodinger?

Summary

How does Veradigm compare to Certara?

Summary

How does Veradigm compare to GoodRx?

Summary

How does Veradigm compare to Teladoc Health?

Summary

How does Veradigm compare to HealthStream?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradigm (MDRX) Competitors

MDRX vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does Veradigm compare to Schrodinger?

Is MDRX or SDGR more profitable?

Does the media refer more to MDRX or SDGR?

Which has better earnings & valuation, MDRX or SDGR?

Do analysts rate MDRX or SDGR?

Which has more volatility & risk, MDRX or SDGR?

Do institutionals & insiders believe in MDRX or SDGR?

Summary

How does Veradigm compare to Certara?

Which has more risk and volatility, CERT or MDRX?

Do institutionals and insiders hold more shares of CERT or MDRX?

Is CERT or MDRX more profitable?

Do analysts rate CERT or MDRX?

Does the media favor CERT or MDRX?

Which has better earnings & valuation, CERT or MDRX?

Summary

How does Veradigm compare to GoodRx?

Does the media refer more to MDRX or GDRX?

Do insiders & institutionals believe in MDRX or GDRX?

Which has better valuation and earnings, MDRX or GDRX?

Which has more volatility & risk, MDRX or GDRX?

Is MDRX or GDRX more profitable?

Do analysts rate MDRX or GDRX?

Summary

How does Veradigm compare to Teladoc Health?

Do analysts recommend TDOC or MDRX?

Which has higher valuation & earnings, TDOC or MDRX?

Do insiders and institutionals believe in TDOC or MDRX?

Is TDOC or MDRX more profitable?

Does the media prefer TDOC or MDRX?

Which has more risk and volatility, TDOC or MDRX?

Summary

How does Veradigm compare to HealthStream?

Do analysts recommend MDRX or HSTM?

Is MDRX or HSTM more profitable?

Does the media favor MDRX or HSTM?

Which has better earnings and valuation, MDRX or HSTM?

Do institutionals & insiders have more ownership in MDRX or HSTM?

Which has more volatility and risk, MDRX or HSTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDRX vs. The Competition

Veradigm Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools